共 50 条
Idiopathic pulmonary fibrosis
被引:1385
|作者:
Richeldi, Luca
[1
,2
,3
]
Collard, Harold R.
[4
]
Jones, Mark G.
[2
,3
]
机构:
[1] Univ Cattolica Sacro Cuore, Fdn Policlin A Gemelli, Unita Operat Complessa Pneumol, I-00168 Rome, Italy
[2] Univ Southampton, Natl Inst Hlth Res, Southampton Resp Biomed Res Unit, Southampton, Hants, England
[3] Univ Southampton, Clin & Expt Sci, Southampton, Hants, England
[4] Univ Calif San Francisco, Dept Med, San Francisco, CA USA
来源:
基金:
英国惠康基金;
关键词:
MUC5B PROMOTER POLYMORPHISM;
INTERSTITIAL LUNG-DISEASE;
FORCED VITAL CAPACITY;
CONTROLLED-TRIAL;
GASTROESOPHAGEAL-REFLUX;
ALVEOLAR PROGENITOR;
ACUTE EXACERBATION;
RANDOMIZED-TRIAL;
DOUBLE-BLIND;
RISK-FACTOR;
D O I:
10.1016/S0140-6736(17)30866-8
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
Idiopathic pulmonary fibrosis is a prototype of chronic, progressive, and fibrotic lung disease. Healthy tissue is replaced by altered extracellular matrix and alveolar architecture is destroyed, which leads to decreased lung compliance, disrupted gas exchange, and ultimately respiratory failure and death. In less than a decade, understanding of the pathogenesis and management of this disease has been transformed, and two disease-modifying therapies have been approved, worldwide. In this Seminar, we summarise the presentation, pathophysiology, diagnosis, and treatment options available for patients with idiopathic pulmonary fibrosis. This disease has improved understanding of the mechanisms of lung fibrosis, and offers hope that similar approaches will transform the management of patients with other progressive fibrotic lung diseases.
引用
收藏
页码:1941 / 1952
页数:12
相关论文